Cardiomyopathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For people with Takotsubo Syndrome (TTS) — a temporary heart condition often triggered by stress:
- Written consent has been provided by the patient, or by a parent, guardian, or legal representative on their behalf.
- A diagnosis of TTS has been confirmed by a doctor using recognised medical diagnostic criteria, including unusual heart muscle movement, no significant blockages in the heart arteries, new changes on a heart tracing (ECG) or elevated heart injury markers in the blood, and no evidence of a hormone-producing tumour or heart inflammation.
For people with sepsis — a life-threatening response to infection:
- Written consent has been provided by the patient, or by a parent, guardian, or legal representative on their behalf.
- A diagnosis of sepsis has been confirmed, meaning a serious infection has caused the body to respond in a way that is damaging organs, shown by a significant worsening in an organ failure score used by doctors.
- A diagnosis of septic shock has been confirmed, meaning the patient requires medication to keep blood pressure at a safe level, and blood tests show a build-up of a substance called lactate, indicating the body is not getting enough oxygen.
- The sepsis has caused the heart to function poorly (either in how it pumps or how it relaxes), in a person who had no known heart disease before becoming unwell.
Who may not be able to join:
- There is another explanation for the patient's symptoms that better accounts for their condition.
- For TTS patients: there are reasons why a PET scan (a type of imaging test) cannot safely be performed — including pregnancy, breastfeeding, or plans to become pregnant during the study period.
- The patient has other serious health conditions that mean they are not expected to survive beyond one year.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Rocco A Montone, MD, PhD, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phone: +39-0630154187
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Association between brain activation and clinical profile and outcome in Takotsubo Syndrome
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.